These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21991967)

  • 1. Radiotherapy and androgen deprivation for prostate cancer.
    Créhange G; Bolla M; Maingon P
    N Engl J Med; 2011 Oct; 365(14):1354; author reply 1354-5. PubMed ID: 21991967
    [No Abstract]   [Full Text] [Related]  

  • 2. ACP Journal Club. Adding short-term androgen-deprivation therapy to radiotherapy improved survival in localized prostate cancer.
    Canfield SE
    Ann Intern Med; 2011 Nov; 155(10):JC5-07. PubMed ID: 22084354
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
    Jani AB; Rossi PJ
    Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
    [No Abstract]   [Full Text] [Related]  

  • 4. Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial.
    Di Lorenzo G; Autorino R; Sonpavde G
    Eur Urol; 2015 Dec; 68(6):1098-9. PubMed ID: 26545569
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
    Taneja SS
    J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209521
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
    Taneja SS
    J Urol; 2015 Jun; 193(6):1983. PubMed ID: 25986794
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cancer of the prostate: importance of androgen deprivation and radiotherapy].
    Rentsch CA; Aebersold DM; Merz V; Studer UE
    Rev Med Suisse; 2005 May; 1(19):1303-6. PubMed ID: 15962630
    [No Abstract]   [Full Text] [Related]  

  • 8. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die?
    Small EJ
    J Clin Oncol; 2014 Nov; 32(33):3689-91. PubMed ID: 25311216
    [No Abstract]   [Full Text] [Related]  

  • 9. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heavy ion radiotherapy for prostate cancer -- the role of hormone therapy].
    Suzuki K; Matsui H; Kawamura H; Ohno T
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):159-63. PubMed ID: 25743135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: Docetaxel in high-risk disease.
    Kelsey R
    Nat Rev Urol; 2015 Jul; 12(7):358. PubMed ID: 26077993
    [No Abstract]   [Full Text] [Related]  

  • 13. Docetaxel for advanced prostate cancer: how early to start?
    Armstrong AJ
    Lancet Oncol; 2015 Jul; 16(7):741-2. PubMed ID: 26028517
    [No Abstract]   [Full Text] [Related]  

  • 14. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.
    Galsky MD; Oh WK
    Lancet Oncol; 2013 Jul; 14(8):681-2. PubMed ID: 23742876
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostate cancer therapy: going forwards by going backwards.
    Sweeney C
    Lancet Oncol; 2013 Feb; 14(2):104-5. PubMed ID: 23306099
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonging survival in prostate cancer: chemotherapy will have an important role.
    Parker C; Emberton M
    BJU Int; 2005 Jul; 96(1):2-3. PubMed ID: 15963108
    [No Abstract]   [Full Text] [Related]  

  • 19. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
    Klotz L; Schellhammer P; Carroll K
    BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
    [No Abstract]   [Full Text] [Related]  

  • 20. Hormone resistance in prostate cancer.
    Pilat MJ; Kamradt JM; Pienta KJ
    Cancer Metastasis Rev; 1998-1999; 17(4):373-81. PubMed ID: 10453281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.